Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

← catalyst calendar

NCT07610837 · readout in 322 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

104estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-05-07

actual

When the study began enrolling

Primary completion

2027-07-07

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-07-07

estimated

The whole study's end, after follow-up

First posted

2026-05-28

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Liver Fibrosis
Hepatic Cirrhosis

Interventions

Drug: AZD2389 — also filed as Active IMP
Other: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Absolute change in Enhanced Liver Fibrosis (ELF) score from baseline to week 24

measured 24 weeks

Reported quantity and severity of adverse events (AEs)